Undetectable mannose binding lectin is associated with HRCT proven bronchiectasis in rheumatoid arthritis (RA).
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2019
2019
Historique:
received:
04
07
2018
accepted:
26
03
2019
entrez:
11
4
2019
pubmed:
11
4
2019
medline:
31
12
2019
Statut:
epublish
Résumé
The aim of this study was to ascertain whether mannose binding lectin deficiency is implicated in coexistent rheumatoid arthritis and bronchiectasis and to determine whether undetectable mannose binding lectin confers poorer long-term survival in coexistent rheumatoid arthritis and bronchiectasis or in rheumatoid arthritis in general. A retrospective audit was conducted in a rheumatoid arthritis cohort in which mannose binding lectin had been measured by enzyme linked immunosorbent assay from 2007-11. Rheumatoid arthritis patients with physician diagnosed HRCT proven bronchiectasis were recruited during this time and compared to those with uncomplicated rheumatoid arthritis. Survival from disease onset was recorded in October 2018. Kaplan-Meier survival estimates were performed to assess mortality over time in the two groups. Log rank tests were used for equality of survivor functions. The two groups were demographically comparable. A higher frequency of undetectable mannose binding lectin was observed in coexistent rheumatoid arthritis and bronchiectasis (37.5%) compared to uncomplicated rheumatoid arthritis, (8.9%, P = 0.005). Undetectable mannose binding lectin correlated with a strong trend toward poor survival in rheumatoid arthritis overall (P = 0.057). Cox regression analysis however, showed no difference in the hazard ratio for survival between the two groups when corrected for age, gender, prednisolone use ever, rheumatoid factor status and the full range of MBL concentrations. In summary, undetectable mannose binding lectin is associated with coexistent rheumatoid arthritis and bronchiectasis and correlates with poor survival in rheumatoid arthritis overall. These findings further implicate immunodeficiency in the genesis of bronchiectasis in rheumatoid arthritis.
Identifiants
pubmed: 30970022
doi: 10.1371/journal.pone.0215051
pii: PONE-D-18-19867
pmc: PMC6457565
doi:
Substances chimiques
Antibodies
0
MBL2 protein, human
0
Mannose-Binding Lectin
0
Peptides, Cyclic
0
cyclic citrullinated peptide
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0215051Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Autoimmun Rev. 2005 Jul;4(6):364-72
pubmed: 16081027
EMBO J. 2003 May 15;22(10):2348-59
pubmed: 12743029
Scand J Rheumatol. 2005 Sep-Oct;34(5):359-66
pubmed: 16234183
Br J Rheumatol. 1994 Feb;33(2):118-22
pubmed: 8162474
Arthritis Rheum. 1988 Mar;31(3):315-24
pubmed: 3358796
Clin Exp Immunol. 2005 Dec;142(3):576-84
pubmed: 16297171
Int J Rheum Dis. 2017 Dec;20(12):2003-2011
pubmed: 26200759
Rheumatology (Oxford). 2009 Jan;48(1):65-9
pubmed: 19056797
Ann Rheum Dis. 2011 Apr;70(4):653-9
pubmed: 21131649
Mol Immunol. 2004 Jun;41(2-3):113-21
pubmed: 15159056
Rheumatology (Oxford). 2016 May;55(5):951-2
pubmed: 26667215
J Rheumatol. 2001 Apr;28(4):728-34
pubmed: 11327242
Genes Immun. 2006 Mar;7(2):85-94
pubmed: 16395391
Thorax. 2009 Feb;64(2):150-5
pubmed: 18988662
Radiology. 1994 Nov;193(2):375-82
pubmed: 7972746
PLoS One. 2014 Oct 13;9(10):e110066
pubmed: 25310716
J Allergy Clin Immunol Pract. 2017 Nov - Dec;5(6):1609-1616
pubmed: 28634103
Q J Med. 1967 Apr;36(142):239-51
pubmed: 6034267
Immunol Today. 1994 Feb;15(2):67-74
pubmed: 8155265
Respirology. 2017 Jan;22(1):101-107
pubmed: 27551950
Medicine (Baltimore). 1994 May;73(3):161-70
pubmed: 8190039
Scand J Immunol. 2004 Jul-Aug;60(1-2):23-9
pubmed: 15238070
Br J Rheumatol. 1992 Oct;31(10):691-3
pubmed: 1393376
Intern Med J. 2005 Sep;35(9):548-55
pubmed: 16105157
Br J Rheumatol. 1997 Jun;36(6):689-91
pubmed: 9236680